Retatrutide

From Retapedia, the free peptide encyclopedia
"Retatrutide" redirects here. For other uses, see Retatrutide (disambiguation).
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Retatrutide (also known as Retatrutide or GIP/GLP-1/Glucagon triple agonist) is a performance-enhancing peptide studied for its effects on fat loss, weight loss, triple agonist. Triple receptor agonist (GLP-1/GIP/glucagon) with superior weight loss (24% in trials) vs tirzepatide/semaglutide. Phase 3 trials. Not FDA-approved.

Retatrutide (LY-3437943) is an investigational triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This unique triple-agonist mechanism promotes superior weight loss compared to single or dual agonists by combining appetite suppression, enhanced insulin secretion, improved glucose homeostasis, and increased energy expenditure. Phase 2 trials demonstrated exceptional efficacy with 24.2% mean weight reduction at 48 weeks (12mg dose), significantly outperforming tirzepatide (~21%) and semaglutide (~15%).

Natty status
Retatrutide is classified as not natty. It is prohibited by WADA and most natural bodybuilding federations. Use places the athlete in the enhanced category. See § Natty status.
Contents [hide]
  1. 1 Overview
  2. 2 Mechanism of action
  3. 3 Reported effects
  4. 4 Dosage and administration
  5. 5 Natty status
  6. 6 Research
  7. 7 Related compounds
  8. 8 References
  9. 9 External links

Overview

Beyond weight loss, retatrutide shows promise for treating type 2 diabetes, metabolic-associated steatohepatitis (MASH/NAFLD), with 90% of patients achieving liver fat normalization at highest doses.

Currently advancing through Phase 3 TRIUMPH clinical trials (5,800+ participants) for obesity, obstructive sleep apnea, and knee osteoarthritis.

Not FDA-approved; investigational use only, and because it has no regulatory approval for human therapeutic use anywhere it is prohibited by WADA at all times under category S0 (non-approved substances).

Common side effects include dose-dependent gastrointestinal issues (nausea, vomiting, diarrhea) that typically diminish over time, plus modest heart rate increases (5-10 bpm).

Gradual dose titration over 12-16 weeks minimizes adverse events, with 16% discontinuation rate at highest dose versus 6% at lowest dose.

Mechanism of action

Triple agonist that curbs appetite and raises energy expenditure for 24% weight loss. Improves blood sugar, lowers blood pressure, and normalizes liver fat. Investigational; not FDA-approved.

Reported effects

Effects reported in the literature and from preclinical models include:

  • At the 12mg maximal weekly dose, retatrutide produced a 24.2% reduction in total body weight at 48 weeks in Phase 2 data, with 63% of participants achieving at least 20% body weight loss and a 23.2% reduction in fat mass, ranking best for weight loss among incretin-based agents. [2][3][7] Phase II
  • In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia (HbA1c below 5.7%). [2] Phase II
  • Retatrutide achieved an 82.4% relative reduction in hepatic fat with liver fat normalization in 86% of patients, indicating potent hepatoprotective effects in metabolic dysfunction-associated steatotic liver disease. [2][4] Phase II
  • In a meta-analysis of randomized controlled trials, retatrutide significantly lowered systolic and diastolic blood pressure and reduced total cholesterol, LDL-C, and triglycerides, with no significant effect on HDL-C. [6][2] Phase II
  • By combining central appetite suppression with glucagon-driven peripheral energy expenditure (thermogenesis), the triple-agonist mechanism delivers more potent and durable weight loss than single-pathway therapies limited by compensatory metabolic adaptation. [5][2] Phase II
  • In an accelerated diet-induced steatohepatitis mouse model, retatrutide reduced body weight, ALT, hepatic triglycerides and cholesterol, and hepatic inflammatory markers. [1] Preclinical

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Dosage and administration

⚠
Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

General

  • Phase 2 protocol - Week 1-4: 2mg once weekly (subcutaneous)
  • Phase 2 protocol - Week 5-8: 4mg once weekly
  • Phase 2 protocol - Week 9-12: 8mg once weekly
  • Phase 2 protocol - Week 13+: 12mg once weekly (maximum dose)
  • Lower starting dose (2mg vs 4mg) reduces GI side effects

Alternative titration

  • 1mg, then 2mg, then 4mg, then 6mg, then 8mg (escalate every 4 weeks)

Maintenance range

  • 4-12mg weekly depending on response and tolerability

Natty status

See also: Peptide § Natty status

Retatrutide is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[8] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.

Research

14 active clinical trials on record — highest phase: Phase 3
View on ClinicalTrials.gov · fetched Jul 17, 2026

The peptide has been the subject of 20 studies and reference works collected on this site. The full bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

mots-c Not natty
Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational and WADA-banned; no approved human use.
Ozempic Natty
Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.
Tirzepatide Natty
Dual GIP/GLP-1 agonist. Reduces appetite for up to 21% weight loss. Improves blood sugar and diabetes control. First drug approved for obstructive sleep apnea. GI side effects common.
5-Amino-1MQ Not natty
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.

References

  1. ^ Steatohepatitis preclinical study
  2. a b c d e Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
  3. ^ Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. Recent review
  4. ^ Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. Recent review
  5. ^ Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure. Recent review
  6. ^ Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Recent review
  7. ^ Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. Recent review
  8. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Performance-enhancing substances | Fat loss | Weight loss | Triple agonist | Metabolic health

This page was last updated on July 17, 2026, at 16:24 (UTC).

Research last reviewed on July 17, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.